Ebola Virus Disease: Updated Pathophysiology and Clinical Aspects - Abstract
The aim of this article is to review and update the pathophysiological mechanisms and clinical aspects of the Ebola virus disease including the novel therapeutic measures. Ebola virus, a RNA virus, was discovered in 1976 as “ Zaire ebolavirus “ and currently is responsible for outbreak in the west Africa. The mucin-liked region of the Ebola virus envelope play a significant role in viral infection in non-human primates and humans through attachment of the membrane anchored C-type lectins rather than specific receptors. Both humoral and cellular immunities are responsible for the survival. Several novel chemotherapeutics are developed and progressive, such as ZMapp, PMOs, BCX-4430, AVI-602, T-705, TMK-Ebola, CMX-001, etc.Health education and counseling of the communities should be implemented, particularly, distance education to reduce the burden of the Ebola-virus-disease stigmatization. Nevertheless, strategic prevention of this virus is the most significant control measures.